

1 **Modelling treatment effects for gonorrhoea**

2

3

4 Pavithra Jayasundara^{a*}, David. G. Regan^b, Philip Kuchel^c, James. G. Wood^a

5 ^a School of Population Health, UNSW Sydney, NSW, Australia.

6 ^b The Kirby Institute, UNSW Sydney, NSW, Australia.

7 ^c School of Life and Environmental Sciences, University of Sydney, NSW, Australia.

8 *Corresponding author: pavi91jayasundara@gmail.com

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30 **Abstract**

31

32 *Neisseria gonorrhoeae* (NG) bacteria have evolved resistance to many of the
33 antibiotics that have been used successfully to treat gonorrhoea infection. To gain a better
34 understanding of potential treatment options for gonorrhoea, we extend a previously
35 developed within-host mathematical model to integrate treatment dynamics by accounting for
36 key pharmacokinetic (PK) and pharmacodynamic (PD) features. This extended model was
37 used to investigate different treatment regimens for two potential treatment options, namely,
38 monotreatment with gepotidacin, and dual treatment with gentamicin and azithromycin. The
39 simulated treatment success rates aligned well with the, albeit limited, clinical trial data that
40 are available. The simulation results indicated that antibiotic treatment failure is associated
41 with failure to successfully clear intracellular NG (NG residing within epithelial cells and
42 neutrophils) and that extracellular PK indices alone cannot differentiate between treatment
43 success or failure. We found that the index defined by the ratio of area under the curve to
44 minimum inhibitory concentration (AUC/MIC) index $> 150h$, evaluated using intracellular
45 gepotidacin concentration, successfully distinguished between treatment success and failure.
46 For the dual treatment regimen, AUC/MIC index $> 140h$ evaluated using the simulated single
47 drug concentration, representing the combined effect of gentamicin and azithromycin with
48 the Loewe additivity concept, successfully differentiated between treatment success and
49 failure. However, we found this PK threshold associated with dual treatment to be less
50 informative than in the gepotidacin monotreatment case as a majority of samples below this
51 threshold still resulted in infection clearance. Although previous experimental results on the
52 killing of intracellular NG are scarce, our findings draw attention to the importance of further
53 experiments on antibiotic killing of intracellular NG. This will be useful for testing putative
54 new anti-gonorrhoea antibiotics.

55

56 **Author Summary**

57

58 Gonorrhoea is a sexually transmitted infection caused by bacteria of the species
59 *Neisseria gonorrhoeae* (NG). Although gonorrhoea can be easily treated using antibiotics,
60 due to the propensity of NG to acquire resistance to antimicrobials, available treatment
61 options have greatly diminished and most of the antibiotics used to treat infection in the past
62 are now removed from treatment recommendations. As clinical trials have limitations in
63 terms of expense, duration and ethical constraints they are not ideal for optimising doses,
64 regimens and drug combinations. In this case, simulations through within-host mathematical
65 models are useful in determining the effective dosing regimens and to explore intracellular
66 treatment effects for which there is little experimental evidence. Our simulations identified
67 the importance of treating intracellular NG (NG residing within neutrophils and epithelial
68 cells) and the importance of considering intracellular pharmacokinetic indices when
69 differentiating treatment success and failure. With the use of this model, we can simulate a
70 range of different treatment regimens and drug combinations to assess their effectiveness at
71 various values of the minimum inhibitory concentration which can potentially be used to
72 guide future clinical trial design.

73

74

75

76

77

78

79

80

81

82

83

84 **Introduction**

85 Gonorrhoea is a sexually transmitted infection caused by bacteria of the species
86 *Neisseria gonorrhoeae* (NG). Since the beginning of the antibiotic era, NG has progressively
87 developed resistance to the classes of drugs used to treat gonorrhoea, and current treatments
88 are now under threat with few alternatives of proven safety and efficacy [1, 2]. Drug resistant
89 NG has become a major public health concern [3, 4] and the development of new treatment
90 options and prophylactic vaccines is seen as increasingly important in population control of
91 gonorrhoea.

92 In clinical trial settings both gepotidacin (GEP) [5, 6] and gentamicin (GEN) +
93 azithromycin (AZM) dual treatment [7-9] have shown potential for treating urethral NG
94 infection. Gepotidacin is a novel triazaacenaphthylene bacterial type II topoisomerase
95 inhibitor while azithromycin is a macrolide and gentamicin is an aminoglycoside. Both
96 macrolides and aminoglycosides work by disrupting bacterial protein synthesis by inhibiting
97 ribosome functionality [10]. Clinical trials report much higher treatment effectiveness using
98 dual therapy with gentamicin + azithromycin (100% cure rate [8]) than with gentamicin
99 monotherapy (68-98% cure rate [11]), but similar effectiveness to using azithromycin
100 monotherapy (99.2% cure rate [12]). By comparing the minimum inhibitory concentration
101 (MIC) of azithromycin and gentamicin on NG strains under monotherapy and dual therapy,
102 the *in vitro* study by Xu et al. [13] has shown that when used in combination, gentamicin can
103 decrease the progression of the development of azithromycin resistance. This combination
104 therapy is recommended as an alternative treatment for patients who cannot be treated with
105 the recommended treatment ceftriaxone, due to infection with ceftriaxone resistant strains
106 [13], allergy or unavailability of ceftriaxone.

107 Although clinical trials are considered the gold standard for evaluating the safety and
108 effectiveness of new drugs, they have limitations in terms of expense, duration and ethical

109 constraints, which compromise their utility for optimising doses, regimens and drug
110 combinations [14]. In this case, simulations through compartment pharmacokinetic (PK)/
111 pharmacodynamic (PD) models such as those used in the study by Chisholm et al. [15] are
112 useful in determining effective dosing regimens. In the context of NG, a within-host
113 mechanistic model has the potential to explore intracellular treatment effects for which there
114 is little experimental evidence. In our previous work on within-host modelling of natural NG
115 infection [16], we observed that intracellular survival and replication of NG appears to be a
116 key factor in prolonging untreated infection. Therefore, it is of interest to consider how
117 treatment resolves infection while accounting for intracellular NG states.

118 In this context intracellular PK/PD effects appear likely to be essential in guiding the
119 design of treatment regimens. However, while experimental studies of extracellular PK/PD
120 effects for NG infection (e.g., [17, 18]) have been conducted, we were unable to find any
121 studies that explored intracellular PK/PD effects in the context of NG infection.

122 In this study, we extend the mathematical model of male urethral NG infection
123 developed in Jayasundara et al. [16] to include antibiotic treatment effects. Here we also
124 investigate the impact of intracellular NG in determining MIC for treatments evaluated in
125 recent trials as future options: different dosing strategies using monotherapy with
126 gepotidacin (GEP) and dual treatment with gentamicin (GEN) + azithromycin (AZM).
127 Finally, we analyse intracellular PK/PD dynamics for these regimens and determine
128 intracellular drug concentration levels required for treatment success.

129 **Materials and Methods**


130

131 *Mathematical model of antibiotic treatment*

132

133 In Jayasundara et al. [16], we developed a deterministic compartmental within-host
134 transmission model to describe untreated symptomatic male urethral infection with NG. In

135 that model, four NG states (unattached NG (B), NG attached to epithelial cells (B_a), NG
136 internalised within epithelial cells (B_i) and NG surviving within polymorphonuclear
137 leukocytes (PMN) (B_s)) and the innate immune response mediated by PMN are used to
138 describe the infection process. In this study, we extend this model to include treatment effects
139 by applying PK/PD principles. Treatment effects are incorporated in both extracellular (B and
140 B_a) and intracellular NG states (B_i and B_s) using drug-specific Hill functions [19], with
141 differing concentrations of drug in the extracellular and intracellular environments. The Hill
142 function parameters are estimated using the NG growth data reported in the *in vitro* time-kill
143 experiments for gentamicin and azithromycin conducted by Foerster et al. [19] and, for
144 gepotidacin, in the study by Farrell et al. [20]. Further details are described in Appendix S1
145 Section S1. The dual treatment effects of gentamicin and azithromycin are modelled using the
146 concept of Loewe additivity as these drugs have similar targets and mechanisms of action [7,
147 21]. When modelling gepotidacin concentration, we adopt a one-compartment model [22] as
148 has been applied by So et al. [23] where we assume that drug concentration declines
149 exponentially on a time-scale determined by the half-life of the drug. However, for
150 gentamicin [24, 25] and azithromycin [26, 27], we adopt a two-compartment model to
151 account for more complex intracellular drug distribution and accumulation. Model specific
152 parameter values are given in Table 1, with the treatment model described in greater detail in
153 the Appendix S1 and the parameters describing untreated infection described in detail in
154 Jayasundara et al. [16]. Fig. 1 provides a schematic illustration of the natural infection model
155 with the added treatment effects.



156

157 Fig 1: Schematic illustration of the within-host NG infection model including antibiotic
 158 treatment. Arrows indicate transitions between model states (boxes). Antibiotic- and
 159 PMN-mediated killing of NG are denoted as d_3 and d_a , respectively (for killing by
 160 PMN see Jayasundara et al. [16]). Explicit intracellular antibiotic compartments are
 161 included for gentamicin and azithromycin (see Section ‘Mathematical model of
 162 antibiotic treatment’), with transitions between extra and intracellular drug
 163 concentrations (dashed lines) applying only for these two drugs.

164 Table 1: Model parameter values for the three antibiotics considered in this study: gepotidacin
 165 (GEP), gentamicin (GEN) and azithromycin (AZM).

Symbol	Parameter (units)	Drug	Point Estimate (LHS range)	References/Comments
D	Initial antibiotic dose (mg)	GEP	1500 / 3000	Trial doses [5, 6].
		GEN	240	Trial doses [28, 29].
		AZM	1000	CDC recommended dose for dual treatment [30].
b_a	Bioavailability	GEP	0.44 (0.38 – 0.5)	[31, 32]
		GEN	1	Given intramuscularly [33].
		AZM	0.37	[27]
V_d	Volume of distribution (L)	GEP	188.7	[31]
		GEN	16.8 (10 - 20)	[34]
		AZM	3219 (1593 - 5475)	[35]
f_u	Fraction unbound	GEN	0.85 – 1	[36]
		AZM	0.88	[37]
		GEP	0.76	[38]
α	The ratio of intracellular to extracellular drug concentration	GEP	1.8 (1.5 – 2.5)	[39]
$C_e(0)$	Initial extracellular drug concentration level (mg/L)	GEP	2.64 (2.43 – 3.04)	Computed using the formula $\frac{D \times b_a \times f_u}{V_d}$ [40]
		GEN	14.29 (10.21 – 23.76)	

		AZM	10.85 (9.31 – 13.02)	
$C_i(0)$	Initial intracellular drug concentration level (mg/L).	GEP	4.75 (3.65 – 7.6)	Computed using the formula $\alpha \times C_e(0)$ [15]
		GEN	0	Drug enters from the extracellular compartment.
		AZM	0	
k_{12}	Transfer rate constant from the extracellular to intracellular compartment (h^{-1})	GEN	0.04 (0.03 – 0.04)	Point estimate from Schentag et al. [41], range refined via calibration with susceptibility breakpoint. Point estimate from Ripa et al. [35], range refined via calibration with susceptibility breakpoint.
		AZM	0.12 (0.10 – 0.18)	
k_{21}	Transfer rate constant from the intracellular to extracellular compartment (h^{-1})	GEN	0.01 (0.008 – 0.016)	[41]
		AZM	0.04 (0.03 – 0.06)	Point estimate from Ripa et al. [35], range refined via calibration with susceptibility breakpoint.
V_e	Volume of the extracellular compartment (L)	AZM	569 (485 – 779)	Point estimate from Ripa et al. [35], range refined via calibration with susceptibility breakpoint.
		GEN	0.95 (0.60 – 1.29)	Point estimate from Schentag et al. [41], range refined via calibration with susceptibility breakpoint.
V_i	Volume of the intracellular compartment (L)	AZM	1779 (981– 1916)	Point estimate from Ripa et al. [35], range refined via calibration with susceptibility breakpoint.
		GEN	0.23 (0.18 – 0.27)	[41]
δ	Rate constant of drug elimination (h^{-1})	GEP	0.06 (0.05 – 0.07)	Point estimate as $\frac{\log(2)}{\text{half-life}}$ using Negash et al. [31]. The lower and upper limit of the LHS ranges are based on Hossain et al. [42] and Tiffany

				et al. [32] respectively.
		GEN	0.14 (0.11 – 0.18)	Elimination rate constant in Schentag et al. [41].
		AZM	0.08 (0.05 – 0.10)	Elimination rate constant in Ripa et al. [35].
φ_{min}	Minimum bacterial growth rate constant in the presence of antibiotic (h^{-1})	GEP	-0.53 (-0.64, -0.46)	Estimated by fitting to data in Farrell et al. [20].
		GEN	-8.18 (-10.00, -6.35)	Estimated by fitting to data in Foerster et al. [19].
		AZM	-1.50 (-2.06, -0.99)	
k_H	The Hill coefficient	GEP	2.47 (1.78, 3.64)	Estimated by fitting to data in Farrell et al. [20].
		GEN	1.70 (1.14, 2.64)	Estimated by fitting to data in Foerster et al. [19].
		AZM	0.91 (0.70, 1.32)	
φ_{max}	Maximum bacterial growth rate constant in the absence of antibiotic (h^{-1})	GEP	0.79 (0.76 – 0.84)	Estimated by fitting to data in Farrell et al. [20].
		GEN	0.89 (0.82 – 0.91)	Estimated by fitting to data in Foerster et al. [19].
		AZM	0.63 (0.61 – 0.69)	
MIC	Minimum inhibitory concentration (mg/L)	GEP	0.26 (0.20, 0.32)	Estimated by fitting to data in Farrell et al. [20].
		GEN	0.24 (0.17, 0.32)	Estimated by fitting to data in Foerster et al. [19].
		AZM	0.03 (0.02, 0.33)	

166 ***Incorporation of parametric uncertainty***

167

168 To account for parametric uncertainty across the natural infection model, in
169 Jayasundara et al. [16] we selected 5402 parameter sets, generated using Latin hypercube
170 sampling (LHS), which met the relevant outcome criteria for the natural time-course of
171 infection (here we index these LHS parameter sets as $i = 1, 2, \dots, 5402$). To incorporate
172 parameter uncertainty that is related to treatment, we extend this previous analysis by also
173 simulating from the ranges that are associated with the treatment parameters. We achieve this
174 by first generating 5402 uniform LHS samples (indexed as $j = 1, 2, \dots, 5402$) for the PK/PD
175 parameters using the parameter ranges derived from relevant literature and summarised in
176 Table 1 and Appendix S1, Table S2. Then to incorporate both natural infection and treatment-
177 related parametric uncertainty, the LHS parameter sets that satisfy the indexing $i = j$ are
178 combined to result in 5402 sets of parameter values. Using these 5402 samples, we assess the
179 modelled infection clearance times.

180 ***Calibrating PK/PD parameters using susceptibility breakpoints.***

181

182 Explicitly capturing the development of antibiotic resistance would require
183 considerable model extension with very limited data availability. Therefore, in this study,
184 rather than directly modelling processes relating to antibiotic resistance, we vary the MIC as
185 a proxy for changes in the susceptibility to a given treatment [43, 44]. To capture the notion
186 of decreased susceptibility (or increased resistance) to treatment, we explore the effect of
187 treatment via the MIC parameter in the Hill function (from here on referred to simply as the
188 ‘MIC’), which we increase gradually from the antibiotic-specific MIC values estimated as
189 described in Section ‘Mathematical model of antibiotic treatment’ for a susceptible NG
190 strain. To this end, we determine a ‘model-derived susceptibility breakpoint’ such that for
191 MIC below and above the breakpoint, the infection clears in ≤ 7 days and > 7 days,

192 respectively (infection clearance threshold, as described in Section ‘Simulated treatment
193 strategies’). These model-derived breakpoints were then calibrated to reproduce the empirical
194 breakpoints and thereby refine the ranges of the parameters that are influential in determining
195 the model-derived susceptibility breakpoints (details of calibration are provided in the
196 Appendix S1, Section S3). Here, we define ‘empirical breakpoints’ as the relevant
197 susceptibility breakpoints for azithromycin published by the Clinical and Laboratory
198 Standards Institute (CLSI) (1mg/L [45]) and the European Committee on Antimicrobial
199 Susceptibility Testing (EUCAST) (0.5mg/L [46]). For gentamicin, a susceptibility breakpoint
200 of 4mg/L is defined based on epidemiological and clinical observations in Malawi as reported
201 in the study by Brown et al. [47]. Furthermore, Brown et al. [47] defines intermediate
202 susceptibility for gentamicin for MIC 8-16mg/L and resistance for MIC ≥ 32 mg/L [47]. For
203 gepotidacin which is not currently used in clinical practice, we use the breakpoints
204 determined in the clinical trials conducted by Taylor et al. [5] and Scangarella-Oman et al.
205 [6].

206 *Simulated treatment strategies*

207

208 In this study, we simulate the effectiveness of the single and multiple dose treatment
209 strategies summarised in Tables 3 and 4. Here, we consider strategies that have been
210 previously tested in clinical trials and compare the simulated treatment effectiveness with
211 clinical trial results as well as using the model to simulate the effectiveness of several novel
212 multiple-dose strategies. Therefore, as previously tested strategies, for gepotidacin we
213 analyse the effectiveness of 1500mg and 300mg single dose strategies which are tested in the
214 clinical trials Taylor et al. [5] and Scangarella-Oman et al. [6]. For the dual treatment
215 combination we test 240mg GEN + 1g AZM strategy tested in the clinical trial Kirkcaldy et
216 al. [8] and 240mg GEN + 2g AZM strategy tested in Rob et al. [9].

217 Treatment is initiated at the peak NG load as identified in our model of untreated
218 infection (at 3.6 days post-infection in the base case) [16], at which point we assume
219 symptoms to be apparent. We classify simulations in which infection is cleared in ≤ 7 days as
220 treatment success, as used in recent clinical trials [6, 48, 49] indicating this timeframe as
221 appropriate to bound successful infection clearance. Simulated infections are assumed to be
222 cleared when the total bacterial load ($B + B_a + B_i + B_s$) falls below 10 bacteria, as used in
223 Jayasundara et al. [16].

224 Any regimen that is approved for the treatment of gonorrhoea should have $\geq 95\%$
225 treatment efficacy [12, 50]. Here, we adopt an analogous definition in terms of our
226 simulations whereby for a given MIC value if $\geq 95\%$ of simulations that are generated from
227 our LHS samples achieve treatment success we consider that particular treatment strategy to
228 be effective. We henceforth define simulated ‘treatment effectiveness’ as the proportion of
229 model simulations that result in successful infection clearance. We note that the sources of
230 variation present in our model are not directly comparable to the variability observed during
231 the treatment of natural human infection and these percentages cannot be directly interpreted
232 as estimates of treatment effectiveness.

233 ***Extracellular vs intracellular susceptibility breakpoints***

234

235 To understand potential differences between *in vitro* and *in vivo* clearance behaviour,
236 we compare the susceptibility breakpoints derived from sub-models of increasing complexity
237 starting with only extracellular states and progressing to the full model involving epithelial
238 cells and PMN.

239 Model A reflects an *in vitro* time-kill study, in which extracellular NG but no host
240 cells (epithelial cells or PMN) are present. In simulations, NG are allowed to grow
241 exponentially and the drug concentration is kept constant (no drug decay), similar to the

242 experimental design used in the *in vitro* study by Foerster et al. [19]. In Model B, epithelial
243 cells are added, leading to the inclusion of unattached NG, NG attached to epithelial cells and
244 NG internalised within epithelial cells. In model C, NG interaction with epithelial cells is
245 removed but the PMN response and NG survival within PMN are included in the simulations.
246 In models B and C and the full-treatment model, logistic constraints on growth are applied as
247 described previously in Jayasundara et al. [16] and the drug concentration varies over time as
248 described above in Section ‘Mathematical model of antibiotic treatment’. Comparisons of the
249 derived susceptibility breakpoints are then made between the sub-models and the full model
250 for the same initial extracellular drug concentration.

251 ***PK indices***

252

253 To compare the effectiveness of differing gepotidacin treatment regimens, we
254 evaluate three PK indices: time above the MIC (t_{MIC}); the ratio of area under the drug
255 concentration curve to the MIC (AUC/MIC); and the ratio of peak drug concentration to the
256 MIC ($C_{\text{max}}/\text{MIC}$). The area integrated over the total drug concentration curve
257 ($\text{AUC}_{0-\infty}/\text{MIC}$) is used as the default AUC/MIC index but we also test the area under the
258 curve above the MIC (removing the area below the MIC from the total area under the curve)
259 and AUC over a fixed time period of 7 days ($\text{AUC}_{0-7}/\text{MIC}$) as alternative indices (see
260 Appendix S1, Section S7.3). For multiple dose strategies, we also calculate the total time the
261 drug concentration remains above the MIC (t_{MIC}) and this is used as the default index of
262 t_{MIC} , and additionally consider some alternative definitions of t_{MIC} in the Appendix S1,
263 Section S7.3. We calculate the three PK indices separately for intracellular and extracellular
264 drug concentrations labelling these indices with the subscripts ‘in’ and ‘ex’ (e.g., $t_{\text{MIC}_{\text{in}}}$,
265 $t_{\text{MIC}_{\text{ex}}}$).

266 Similarly, for the dual treatment option we calculate the ratio of area under the drug
267 concentration curve to the MIC (AUC/MIC_h) using the simulated single drug concentration
268 representing the combined effect of gentamicin and azithromycin calculated using the Loewe
269 additivity concept (using Appendix S1, Equation S4). Loewe additivity combines both
270 antibiotics, gentamicin and azithromycin into a single drug of higher effect. Here, MIC_h
271 refers to the MIC of the drug having the higher effectiveness out of gentamicin (4mg/L) and
272 azithromycin (1mg/L) at each time point. This PK index is calculated in both the extracellular
273 and intracellular environments and a threshold is determined to distinguish treatment success
274 and failure.

275 *Non-adherence to treatment strategies*

276

277 For multiple dose strategies of gentamicin which extend over 3 days, we also test the
278 impact of limited non-adherence by the patient. Specifically, we consider a uniformly
279 distributed delay of between 0 and 24h to the 2nd dose in comparison to the recommended
280 schedule, with subsequent doses then taken at the correct spacing from the previous dose.
281 Treatment efficacy is analysed when 15%, 25% 50%, 75% and 100% of the simulations
282 deriving from the LHS samples are assumed to be subject to non-adherence.

283 **Results**

284 *Extracellular vs intracellular susceptibility breakpoint*

285

286 For each of the sub-models described in Section ‘Simulated treatment strategies’ we
287 determine drug-specific model-derived susceptibility breakpoints, with simulation results
288 based on point estimates summarised together with those from the full treatment model in
289 Table 2. In addition, breakpoint ranges derived from simulations using all LHS parameters
290 are provided for the full model and compared with empirical breakpoints where available.

291

292

293 Table 2: Susceptibility breakpoints (mg/L) derived from the three sub-models and the full
294 model and comparison with empirical breakpoints.

295

Drug	Susceptibility breakpoints (mg/L)				
	Model A	Model B	Model C	Full model point estimate (LHS range)	Empirical breakpoints
GEP	2.55	0.79	0.73	0.64 (0.48 – 1.1)	Not available
AZM	9.35	0.89	0.70	0.69 (0.55 – 1.29)	0.5 [46], 1 [45]
GEN	12.75	1.94	1.74	1.60 (1.51 – 5.54)	4 [47].

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

We observe that with the addition of intracellular compartments the model-derived susceptibility breakpoints are 8-fold, 14-fold and 4-fold lower in the full model as compared to the *in-vitro* model (model A) for azithromycin, gentamicin and gepotidacin respectively. Results for models B (unattached and attached NG and NG within epithelial cells) and C (unattached NG and NG within PMN) are similar to those for the full model, indicating that these large differences in model-derived susceptibility breakpoints for model A compared with the other models is associated with the inclusion of intracellular NG states in simulations.

316 ***Gepotidacin monotreatment.***

317 The results of model simulations for gepotidacin monotreatment are summarised in
 318 Table 3. Gepotidacin regimens that accumulate to 1500mg in total, irrespective of
 319 administration as single or multiple doses, achieve treatment success for NG MIC ≤ 0.5 mg/L,
 320 while most regimens with a total dose of 3000mg achieve success for MIC ≤ 1 mg/L. In our
 321 model, clearance behaviour is invariant when the MIC/dose ratio is held fixed (see Appendix
 322 S1, Section S7.1), with higher dose strategies of 4.5g and 6g gepotidacin being successful for
 323 MIC ≤ 1.5 mg/L and MIC ≤ 2 mg/L, respectively (Appendix S1, Table S3).

324 Some of the multiple dose regimens for gepotidacin we investigate have not yet been
 325 tested in clinical trials. In the majority of simulated regimens, treatment success/failure is
 326 consistent across single and multiple dose strategies with the same total dose amount for the
 327 same NG MIC parameter. However, daily administration of 500mg for 6 days at
 328 MIC=1mg/L, resulted in treatment failure (~66% of simulations cleared), despite treatment
 329 success with other 3000mg total dose regimens simulated here. We discuss this result in more
 330 detail in the next section.

331

332 Table 3: Percentage of simulations using LHS samples (out of 5402) that clear infection in
 333 ≤ 7 days when using single and multiple dose gepotidacin treatment strategies.

Treatment strategy	Percentage of simulations that clear infection				
	MIC (mg/L)				
	0.05	0.125	0.25	0.5	1
1500mg single dose	100.0	100.0	99.9	95.0	20.8
500mg \times 3, 8h apart	100.0	100.0	100.0	99.2	38.1
500mg \times 3, 12h apart	100.0	100.0	100.0	99.6	40.4

500mg × 3, 24h apart	100.0	100.0	100.0	98.9	14.0
3000mg single dose	100.0	100.0	100.0	99.9	95.0
500mg × 6, 8h apart	100.0	100.0	100.0	100.0	99.8
500mg × 6, 12h apart	100.0	100.0	100.0	100.0	99.5
500mg × 6, 24h apart	100.0	100.0	100.0	100.0	66.2
1500mg × 2, 8h apart	100.0	100.0	100.0	100.0	95.7
1500mg × 2, 12h apart	100.0	100.0	100.0	100.0	98.4
1500mg × 2, 24h apart	100.0	100.0	100.0	100.0	99.3

334

335

336

337

338


339

340

341 *Effectiveness of different dosing strategies of gepotidacin*

342

343 Comparison of PK indices across the gepotidacin regimens provides insight into why
344 the simulated 500mg × 6, at 24h interval regimen failed treatment at MIC=1mg/L whereas
345 other regimens with the same total drug did not. In this regimen, the intracellular drug
346 concentration was maintained above the MIC ($t_{MIC_{in}}$) for only 47% of the dosing interval and
347 correspondingly bacterial load spiked as the drug concentration fell below the MIC (Fig. 2).
348 By comparison, for 500mg × 6 dosing regimens at intervals of 8 and 12h the intracellular
349 drug concentration is above 1mg/L for 100% and 94% of the dosing interval, respectively.



350

351

352 Fig 2: Effect of gepotidacin dosing intervals of 8,12 and 24h in a 500mg × 6 schedule on (a)
353 intracellular drug concentration and (b) total NG load. Dashed lines indicate MIC of
354 1mg/L (a) and infection clearance cut-off of 10 bacteria (b). Parameter values are
355 specified in Table 1.

356 The simulation results in Table 3 also suggest that in most cases, multiple dose
357 regimens clear infection in a higher fraction of simulations when the total dose is held fixed.
358 For instance, at a MIC for gepotidacin of 0.5mg/L infection clearance occurs in 95.0% of
359 simulations with a 1500mg single dose compared with >98% simulations in 500mg × 3
360 regimens at 8, 12 and 24h intervals. Here, the multiple dose strategies achieve an increased
361 $t_{MIC_{in}}$ in comparison to the single dose strategy (Appendix S1, Fig. S7). The highest value of
362 this PK index also occurs with the most effective dosing interval (24h) at MIC of 1mg/L with
363 a total dose of 3000mg split into two (1500mg × 2 given 8, 12 or 24h apart) as shown in
364 Appendix S1, Fig. S7.


365 *PK indices to differentiate treatment success using gepotidacin.*

366

367 We also attempt to determine treatment success and failure based on PK indices
368 evaluated using extracellular and intracellular gepotidacin concentration. Extracellular PK

369 indices fail to sharply distinguish simulations in which treatment succeeds from those where
370 it fails, as there are simulations with the same PK index value but opposite treatment
371 outcomes (Fig.3). The ratio of peak intracellular drug concentration to MIC (C_{\max}/MIC_{in})
372 index is also unable to discriminate between success or failure to clear infection. In contrast,
373 intracellular indices for the ratio of area under the total drug concentration curve to the MIC
374 (AUC/MIC_{in}) and time above the MIC ($t_{MIC_{in}}$), clearly differentiate between treatment
375 success and failure. However, while a common cut-off across all dosing schedules could be
376 obtained with the AUC/MIC_{in} index (Fig.3), the $t_{MIC_{in}}$ cut-off varies by dosing schedule. This
377 behaviour is preserved under the alternative definition whereby only the AUC above the MIC
378 is considered (Appendix S1, Fig. S9). Dose-dependence also occurs for other forms of the
379 $t_{MIC_{in}}$ cut-off (Appendix S1, Fig. S8). We therefore focus on the AUC/MIC_{in} index for
380 gepotidacin in regard to determination of a threshold parameter.

381 From the simulated concentration profiles, we observe that treatment success for
382 gepotidacin occurs in simulations where $AUC/MIC_{in} > 150h$ (Fig.3). We note that there are 6
383 simulations with AUC/MIC_{in} in the range of 147-150h that fail to clear the infection
384 (simulation behaviour shown in Appendix S1, Fig. S10). For these unsuccessful simulations,
385 the total bacterial load declines very close to the infection clearance threshold (to ~11
386 bacteria in some instances), but does not meet our criterion for infection clearance (total NG
387 load <10 bacteria). This further supports the $AUC/MIC_{in} > 150h$, as a suitable threshold to
388 differentiate between simulated treatment success and failure.



389

390

391 Fig 3: Comparison of PK/PD indices to differentiate treatment success and failure. The ratio

392 of area under the curve to the MIC are shown for: (a) intracellular and (b)

393 extracellular drug concentration; the time above the MIC calculated for

394 intracellular (c) and extracellular (d) drug concentration; the ratio of peak drug

395 concentration to the MIC for intracellular (e) and extracellular (f) drug
396 concentration.

397 ***Dual treatment with gentamicin + azithromycin***

398

399 *Effectiveness of different dosing strategies of gentamicin + azithromycin*

400

401 The effectiveness of dual treatment with gentamicin + azithromycin across single and
402 multiple dose strategies is summarised in Table 4. For the same total dose amount, multiple
403 doses of gentamicin and multiple doses of azithromycin result in similar effectiveness to the
404 single dose strategy, with limited sensitivity to dosing frequency as well. Among the tested
405 strategies, only 240mg \times 3 gentamicin, given 24h apart in combination with 2g single dose of
406 azithromycin is effective at high MIC for both gentamicin and azithromycin (16 mg/L and 1
407 mg/L, respectively, Table 4). We also examine the impact of limited non-adherence using the
408 multiple dose strategy of 240mg \times 3 gentamicin, given 24h apart along with 2g single dose of
409 azithromycin. Here, at MIC for gentamicin and azithromycin of 16mg/L and 1 mg/L,
410 respectively, for the 100% non-adherence scenario 94.13% (Appendix S1, Table S4)
411 treatment success is observed showing similar effectiveness (95.45%) to the 100% adherent
412 scenario (Table 4).

413

414

415

416

417

418 Table 4: Percentage of simulations that clear the infection (out of 5402 LHS samples) at
 419 various MIC values with gentamicin (GEN) and azithromycin (AZM) dual therapy
 420 regimens.

Treatment strategy	Percentage of simulations that clear infection					
	(Gentamicin/azithromycin) MIC (mg/L)					
	(4/0.5)	(4/1)	(8/0.5)	(8/1)	(16/0.5)	(16/ 1)
Strategies with gentamicin total accumulation of 240mg						
240mg GEN + 1g AZM	95.6	85.9	86.9	61.1	78.5	39.7
240mg GEN + 2g AZM	99.7	95.6	98.8	86.9	97.7	78.5
80mg GEN × 3, 8h apart + 1g AZM single dose	95.6	86.0	86.9	61.1	78.5	39.8
120mg GEN × 2, 8h apart + 1g AZM single dose	95.6	86.2	86.9	61.9	78.8	39.8
Strategies with gentamicin total accumulation of 480mg						
120mg GEN × 2, 12h apart for 2 days + 1g AZM single dose	99.8	99.3	97.9	93.7	92.5	76.2
240mg GEN × 2, 24h apart + 1g AZM single dose	99.8	99.2	97.8	93.1	92.1	74.8
Strategies with gentamicin total accumulation of 720mg						
240mg GEN × 3, 24h apart + 1g AZM single dose	99.9	99.7	98.8	96.4	94.5	82.2
240mg GEN × 3, 24h apart + 2g AZM single dose	100.0	99.9	99.9	98.9	99.7	95.5
240mg GEN × 3, 24h apart + 1g AZM × 2, 24h apart	100.0	99.9	99.8	98.5	99.4	93.5

421

422

423


424

425 *PK index to differentiate treatment success using the dual treatment combination of*

426 *gentamicin and azithromycin.*

427

428 We also attempt to distinguish treatment success and failure based on the PK index
 429 evaluated using the single drug resulting from Loewe additivity. Similar to gepotidacin, the
 430 ratio of area under the total intracellular drug concentration curve to the MIC ($AUC/MIC_{h,in}$)
 431 can clearly differentiate between treatment success and failure (Fig. 4). From the simulated
 432 concentration profile of a single drug resulting from Loewe additivity, we observe that all
 433 samples achieving $AUC/MIC_{h,in} > 140h$ successfully clear infection. However, unlike the PK
 434 index threshold related to gepotidacin monotherapy, we observe that a substantial
 435 proportion of simulations successfully clear infection when $AUC/MIC_{h,in} < 140h$.



436

437 Fig 4: Simulated infection clearance based on the ratio of area under the (a) intracellular and

438 (b) extracellular drug concentration resulting from Loewe additivity (AUC/MIC_h) for

439 gentamicin and azithromycin dual treatment option.

440 **Discussion**

441

442 In this study, we develop a within-host mathematical model to describe antibiotic
443 treatment effects while considering NG interactions with host cells. We found that inclusion
444 of intracellular states leads to substantial changes in MIC clearance thresholds as opposed to
445 *in-vitro* NG dynamics alone. The relevance of different intracellular NG states in
446 determining treatment success is a matter of current debate by experts in this field [51]. The
447 difficulty in reaching a consensus on this issue is likely due to limited experimental evidence
448 of the impact of intracellular antibiotic-mediated killing on treatment outcomes. Here, our
449 findings on the model-derived susceptibility breakpoints and treatment effects in the presence
450 of intracellular NG, suggest further experiments assessing the role of intracellular NG in
451 determining treatment success could be valuable. We also analyse the association of PK
452 indices with treatment success and the level of intracellular drug concentration that must be
453 maintained to achieve successful infection clearance. When calculating PK indices relevant to
454 the dual treatment option we introduce a novel approach of using a simulated single drug
455 concentration representing the combined effect of gentamicin and azithromycin calculated
456 using the Loewe additivity concept. However, unlike in the monotreatment case, the
457 threshold relating to dual treatment does not separate treatment success from treatment failure
458 as a majority of samples below our PK index threshold still lead to clearance.

459 In Jayasundara et al. [16], we showed the importance of intracellular NG in
460 prolonging the duration of natural infection and here we show the importance of intracellular
461 antibiotic mediated killing in determining treatment success in our model. The importance of
462 different intracellular NG states (NG within PMN and epithelial cells) in determining
463 treatment success is not as yet resolved [51], due to limited experimental evidence of the
464 impact of intracellular antibiotic-mediated killing on treatment outcomes. Although *in vitro*
465 models such as those developed using immortal cell lines (e.g., HeLa cells) [52] have been

466 used to explore the intracellular behaviour of NG, we are not aware of any study that
467 considers antibiotic interactions with intracellular NG. Here, our findings on the model-
468 derived susceptibility breakpoints in the presence of intracellular NG, suggest further
469 experiments assessing the role of intracellular NG in determining treatment success could be
470 valuable.

471 Building on our simulation results highlighting the importance of intracellular
472 concentrations in treatment success, we found that an intracellular version of the area under
473 the curve index discriminated between treatment success and failure using gepotidacin.
474 Consistent with our findings, a strong correlation between AUC/MIC index and bacterial
475 killing of two gram-positive pathogens (*S.aures* and *S.pneumoniae*) has been reported by
476 Bulik et al. [38]. Although our extracellular index measures align with the calculations based
477 on plasma drug concentrations in Scangarella-Oman et al. [6], their study is limited by
478 sample size with only five NG isolates with MIC for gepotidacin of 1mg/L [53]. However, in
479 our model treatment success and failure could only be clearly differentiated through
480 intracellular indices. This is because, in our model implementation, consistent with limited
481 empirical evidence of intracellular NG populations measured in urethral exudates by Veale et
482 al. [54], a majority of NG reside intracellularly [16] and here, treatment success is observed
483 to be mainly determined through the killing of intracellular NG (Table 2).

484 Our analysis of dual treatment using single doses of gentamicin + azithromycin is
485 comparable, to a certain extent, with the limited data available from clinical trials. The two
486 clinical trials that have been conducted for this drug combination report an overall genital
487 infection treatment success rate of 94% [7] and 100% [8] using 240mg gentamicin combined
488 with 1g and 2g azithromycin doses, respectively. In the clinical trial by Ross et al. [7], 97.7%
489 and 95.7% of isolates had MIC for gentamicin ≤ 4 mg/L and MIC for azithromycin ≤ 0.5 mg/L,
490 respectively. However, in these studies treatment success is not disaggregated into MIC

491 ranges and therefore, a clear comparison cannot be made with our model simulation results
492 for MIC for gentamicin and azithromycin of 4mg/L and 0.5mg/L, respectively.

493 If additional data on antibiotic mediated killing of intracellular NG become available
494 through future experimental studies, analogous for example to the *in vitro* time-kill
495 experiment by Barcia-Macay et al. [55] that analysed drug mediated killing of extracellular
496 and intracellular *S. aureus*, some of our findings on the rates of intracellular NG killing by
497 antibiotics could then be compared with experimental data. Although such experimental
498 studies on antibiotic activity against other intracellular pathogens can be a useful guide it is
499 important to note that the magnitude of intracellular bacteriostatic/bactericidal effects
500 depends on both the pathogen and the drug [56].

501 While most PK parameters (e.g., volume of distribution, drug half-life) are based on
502 plasma drug concentration profiles measured in patients, we have had to rely on *in vitro* data
503 for the PD parameters and some PK parameters. The experimental limitations of these *in*
504 *vitro* studies, such as the use of constant drug concentrations and lack of intracellular
505 bacteria, do not reflect the true *in vivo* environment and add potential for error in these
506 parameters. Reflecting the limited data available, we took a parsimonious approach in
507 assuming that intracellular PK effects for PMN and epithelial cells were the same. Although
508 we recognise that both drug accumulation and penetration can depend on the host cell and
509 tissue type [56, 57] we lacked relevant data to inform different estimates.

510 **Conclusions**

511 In this study, we developed a PK/PD analysis approach to study antibiotic interaction
512 with NG in different cellular states and to assess the effectiveness of novel treatment
513 strategies over a range of MIC values. To the best of our knowledge, this is the first within-
514 host mathematical modelling study that explores the intracellular antibiotic killing of NG.

515 Our findings suggest the importance of considering intracellular dynamics when deciding on
516 treatment regimens as the model-derived susceptibility breakpoints are observed to be
517 substantially impacted by the killing of NG within PMN and epithelial cells. This also draws
518 attention to the potential importance of further experimental studies that capture intracellular
519 PK/PD effects in regard to gonorrhoea treatment. Such investigation into the intracellular
520 antibiotic effects may be useful when developing novel antibiotics for gonorrhoea. In
521 addition, our findings, and the model more generally, may have utility as a tool for
522 identifying treatment regimens to explore further in clinical trials.

523 **References**

- 524 1. Unemo M, Del Rio C, Shafer WM. Antimicrobial resistance expressed by *Neisseria*
525 *gonorrhoeae*: A major global public health problem in the 21st century. *Microbiol Spectr.*
526 2016;4(3). Epub 2016/06/24. doi: 10.1128/microbiolspec.EI10-0009-2015. PubMed PMID:
527 27337478; PubMed Central PMCID: PMC4920088.
- 528 2. Terreni M, Tacconi M, Pregolato M. New Antibiotics for Multidrug-Resistant
529 Bacterial Strains: Latest Research Developments and Future Perspectives. *Molecules.*
530 2021;26(9):2671. PubMed PMID: doi:10.3390/molecules26092671.
- 531 3. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United
532 States, 2019 Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2019.
- 533 4. World Health Organization. Global action plan to control the spread and impact of
534 antimicrobial resistance in *Neisseria gonorrhoeae*. World Health Organization
535 (WHO), Department of Reproductive Health and Research, 2012.
- 536 5. Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, et al.
537 Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2,
538 Randomized, Dose-Ranging, Single-Oral Dose Evaluation. *Clin Infect Dis.* 2018;67(4):504-
539 12. Epub 2018/04/05. doi: 10.1093/cid/ciy145. PubMed PMID: 29617982; PubMed Central
540 PMCID: PMC6070052.
- 541 6. Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, et al.
542 Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single
543 Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused
544 by *Neisseria gonorrhoeae*. *Antimicrob Agents Chemother.* 2018;62(12). Epub 2018/09/27.
545 doi: 10.1128/AAC.01221-18. PubMed PMID: 30249694; PubMed Central PMCID:
546 PMC6256812.
- 547 7. Ross JDC, Brittain C, Cole M, Dewsnap C, Harding J, Hepburn T, et al. Gentamicin
548 compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-

- 549 inferiority trial. *Lancet*. 2019. Epub 2019/05/06. doi: 10.1016/S0140-6736(18)32817-4.
550 PubMed PMID: 31056291.
- 551 8. Kirkcaldy RD, Weinstock HS, Moore PC, Philip SS, Wiesenfeld HC, Papp JR, et al.
552 The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin
553 as treatment of uncomplicated gonorrhoea. *Clin Infect Dis*. 2014;59(8):1083-91. Epub
554 2014/07/18. doi: 10.1093/cid/ciu521. PubMed PMID: 25031289; PubMed Central PMCID:
555 PMCPMC4271098.
- 556 9. Rob F, Klubalová B, Nyčová E, Hercogová J, Unemo M. Gentamicin 240 mg plus
557 azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and
558 pharyngeal gonorrhoea: a randomized controlled trial. *Clin Microbiol Infect*. 2020;26(2):207-
559 12. Epub 2019/08/17. doi: 10.1016/j.cmi.2019.08.004. PubMed PMID: 31419483.
- 560 10. Brooks GF, Carroll KC, Butel JS, Morse SA, Mietzner TA. *Jawetz, Melnick &*
561 *Adelberg's Medical Microbiology*. 26 ed: McGraw-Hill; 2013.
- 562 11. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment:
563 systematic review and meta-analysis. *Postgraduate Medical Journal*. 2013;89(1049):142-7.
564 doi: 10.1136/postgradmedj-2012-050604rep.
- 565 12. Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated
566 gonococcal infections. *Clin Infect Dis*. 1995;20 Suppl 1:S47-65. Epub 1995/04/01. PubMed
567 PMID: 7795109.
- 568 13. Xu W, Zhou Q, Liu J, Zhang Y, Zhu X, Zhu B, et al. In Vitro Study of the Interaction
569 of Gentamicin with Ceftriaxone and Azithromycin against *Neisseria gonorrhoeae* Using Agar
570 Dilution Method. *Antibiotics (Basel)*. 2022;11(8). Epub 2022/08/27. doi:
571 10.3390/antibiotics11081083. PubMed PMID: 36009953; PubMed Central PMCID:
572 PMCPMC9405204.
- 573 14. Hook EW, Newman L, Drusano G, Evans S, Handsfield HH, Jerse AE, et al.
574 Development of new antimicrobials for urogenital gonorrhoea therapy: clinical trial design
575 considerations. *Clin Infect Dis*. 2020;70(7):1495-500. Epub 2019/09/21. doi:
576 10.1093/cid/ciz899. PubMed PMID: 31538646.
- 577 15. Chisholm SA, Mouton JW, Lewis DA, Nichols T, Ison CA, Livermore DM.
578 Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? *J*
579 *Antimicrob Chemother*. 2010;65(10):2141-8. doi: 10.1093/jac/dkq289. PubMed PMID:
580 WOS:000282174800014.
- 581 16. Jayasundara P, Regan DG, Seib KL, Jayasundara D, Wood JG. Modelling the in-host
582 dynamics of *Neisseria gonorrhoeae* infection. *Pathog Dis*. 2019;77(1). Epub 2019/02/17. doi:
583 10.1093/femspd/ftz008. PubMed PMID: 30770529.
- 584 17. Connolly KL, Eakin AE, Gomez C, Osborn BL, Unemo M, Jerse AE.
585 Pharmacokinetic Data Are Predictive of in vivo Efficacy for Cefixime and Ceftriaxone
586 against Susceptible and Resistant *Neisseria gonorrhoeae* Strains in the Gonorrhoea Mouse
587 Model. *Antimicrob Agents Chemother*. 2019. Epub 2019/01/16. doi: 10.1128/AAC.01644-
588 18. PubMed PMID: 30642924.

- 589 18. VanScoy BD, Scangarella-Oman NE, Fikes S, Min S, Huang J, Ingraham K, et al.
590 Relationship Between Gepotidacin Exposure and Prevention of On-Therapy Resistance
591 Amplification in a *Neisseria gonorrhoeae* Hollow-Fiber *In Vitro* Infection Model.
592 Antimicrob Agents Chemother. 2020;AAC.00521-20. doi: 10.1128/aac.00521-20.
- 593 19. Foerster S, Unemo M, Hathaway LJ, Low N, Althaus CL. Time-kill curve analysis
594 and pharmacodynamic modelling for in vitro evaluation of antimicrobials against *Neisseria*
595 *gonorrhoeae*. BMC Microbiol. 2016;16:216. Epub 2016/09/19. doi: 10.1186/s12866-016-
596 0838-9. PubMed PMID: 27639378; PubMed Central PMCID: PMC5027106.
- 597 20. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. In Vitro
598 Activity of Gepotidacin (GSK2140944) against *Neisseria gonorrhoeae*. Antimicrob Agents
599 Chemother. 2017;61(3). Epub 2017/01/11. doi: 10.1128/AAC.02047-16. PubMed PMID:
600 28069643; PubMed Central PMCID: PMC5328517.
- 601 21. Mensforth S, Ross JDC. Should we still use azithromycin for gonorrhoea treatment?
602 Sexual Health. 2019;16(5):442-8. doi: 10.1071/Sh19016. PubMed PMID:
603 WOS:000485740300006.
- 604 22. Rowland M, Tozer TN. Clinical Pharmacokinetics Concepts and Applications:
605 Williams and Wilkins; 1995.
- 606 23. So W, Crandon JL, Nicolau DP. Pharmacodynamic Profile of GSK2140944 against
607 Methicillin-Resistant *Staphylococcus aureus* in a Murine Lung Infection Model. Antimicrob
608 Agents Chemother. 2015;59(8):4956-61. Epub 2015/06/10. doi: 10.1128/AAC.00625-15.
609 PubMed PMID: 26055376; PubMed Central PMCID: PMC4505212.
- 610 24. Tulkens P, Trouet A. The uptake and intracellular accumulation of aminoglycoside
611 antibiotics in lysosomes of cultured rat fibroblasts. Biochem Pharmacol. 1978;27(4):415-24.
612 Epub 1978/02/15. PubMed PMID: 24449.
- 613 25. Tulkens PM. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol
614 Infect Dis. 1991;10(2):100-6. Epub 1991/02/01. PubMed PMID: 1864271.
- 615 26. Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and
616 its intracellular activity under in vivo conditions. Antimicrobial agents and chemotherapy.
617 1996;40(1):75-9. PubMed PMID: 8787883.
- 618 27. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human
619 serum and tissues. J Antimicrob Chemother. 1990;25 Suppl A:73-82. Epub 1990/01/01.
620 PubMed PMID: 2154441.
- 621 28. Brittain C, Childs M, Duley L, Harding J, Hepburn T, Meakin G, et al. Gentamicin
622 versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a
623 randomised trial. Trials. 2016;17(1):558-. doi: 10.1186/s13063-016-1683-8. PubMed PMID:
624 27881151.
- 625 29. Hira SK, Attili VR, Kamanga J, Mkandawire O, Patel JS, Patel MI. Efficacy of
626 gentamicin and kanamycin in the treatment of uncomplicated gonococcal urethritis in
627 Zambia. Sex Transm Dis. 1985;12(1):52-4. Epub 1985/01/01. PubMed PMID: 3890228.

- 628 30. Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases
629 Treatment Guidelines. 2015 January 4th 2018. Report No.
- 630 31. Negash K, Andonian C, Felgate C, Chen C, Goljer I, Squillaci B, et al. The
631 metabolism and disposition of GSK2140944 in healthy human subjects. *Xenobiotica*.
632 2016;46(8):683-702. Epub 2015/11/21. doi: 10.3109/00498254.2015.1112933. PubMed
633 PMID: 26586303.
- 634 32. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. Safety and
635 Pharmacokinetics of Single Escalating IV Doses of GSK2140944, a Novel Bacterial
636 Topoisomerase Inhibitor. Abstr 54th Interscience Conference on Antimicrobial Agents and
637 Chemotherapy; Washington, D.C.2014.
- 638 33. Katzung BG. *Basic and Clinical Pharmacology* 14 ed. United States of America:
639 McGraw-Hill Education; 2018.
- 640 34. Al-Lanqawi Y, Capps P, Abudlmalek K, Al-Anezi K, Thusu A, Sharma P. Clinical
641 pharmacokinetics of gentamicin. Estimation of initial dosing parameters in hospitalized
642 patients at Al-Amiri Hospital Kuwait. *Med Princ Pract*. 2009;18(3):209-16. Epub 2009/04/08.
643 doi: 10.1159/000204352. PubMed PMID: 19349724.
- 644 35. Ripa S, Ferrante L, Prena M. A linear model for the pharmacokinetics of
645 azithromycin in healthy volunteers. *Chemotherapy*. 1996;42(6):402-9. Epub 1996/11/01. doi:
646 10.1159/000239473. PubMed PMID: 8957574.
- 647 36. Bailey DN, Briggs JR. Gentamicin and tobramycin binding to human serum in vitro. *J*
648 *Anal Toxicol*. 2004;28(3):187-9. Epub 2004/04/27. doi: 10.1093/jat/28.3.187. PubMed
649 PMID: 15107149.
- 650 37. Singlas E. [Clinical pharmacokinetics of azithromycin]. *Pathologie-biologie*.
651 1995;43(6):505-11. Epub 1995/06/01. PubMed PMID: 8539072.
- 652 38. Bulik CC, Okusanya ÓO, Lakota EA, Forrest A, Bhavnani SM, Hoover JL, et al.
653 Pharmacokinetic-pharmacodynamic evaluation of gepotidacin against gram-positive
654 organisms using data from murine infection models. 2017;61(2):e00115-16. doi:
655 10.1128/AAC.00115-16 %J *Antimicrobial Agents and Chemotherapy*.
- 656 39. Peyrusson F, Tulkens PM, Van Bambeke F. Cellular Pharmacokinetics and
657 Intracellular Activity of Gepotidacin against *Staphylococcus aureus* Isolates with Different
658 Resistance Phenotypes in Models of Cultured Phagocytic Cells. *Antimicrob Agents*
659 *Chemother*. 2018;62(4). Epub 2018/01/24. doi: 10.1128/AAC.02245-17. PubMed PMID:
660 29358297; PubMed Central PMCID: PMC5913948.
- 661 40. Austin DJ, White NJ, Anderson RM. The dynamics of drug action on the within-host
662 population growth of infectious agents: melding pharmacokinetics with pathogen population
663 dynamics. *J Theor Biol*. 1998;194(3):313-39. Epub 1998/10/21. doi: 10.1006/jtbi.1997.0438.
664 PubMed PMID: 9778442.
- 665 41. Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, et al.
666 Gentamicin disposition and tissue accumulation on multiple dosing. *J Pharmacokinetic*
667 *Biopharm*. 1977;5(6):559-77. Epub 1977/12/01. PubMed PMID: 599407.

- 668 42. Hossain M, Tiffany CA, McDonald M, Dumont EF. Safety and Pharmacokinetics of
669 Repeat Escalating Oral Doses of GSK2140944, a Novel Bacterial Topoisomerase Inhibitor.
670 Abstr 54th Interscience Conference on Antimicrobial Agents and Chemotherapy;
671 Washington,D.C2014.
- 672 43. Kjellander JO, Finland M. Penicillin treatment of gonorrhoeal urethritis. Effects of
673 penicillin susceptibility of causative organism and concomitant presence of penicillinase-
674 producing bacteria on results. *N Engl J Med.* 1963;269:834-6. Epub 1963/10/17. doi:
675 10.1056/NEJM196310172691603. PubMed PMID: 14052266.
- 676 44. Martin JE, Jr., Lester A, Price EV, Schmale JD. Comparative study of gonococcal
677 susceptibility to penicillin in the United States, 1955-1969. *J Infect Dis.* 1970;122(5):459-61.
678 Epub 1970/11/01. doi: 10.1093/infdis/122.5.459. PubMed PMID: 4990947.
- 679 45. Clinical and Laboratory Standards Institute. *Performance standards for antimicrobial*
680 *susceptibility testing*— CLSI supplement M100. 28 ed. CLSI,Wayne, PA, USA2018.
- 681 46. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for
682 interpretation of MICs and zone diameters 2018 2018 [cited 2019 10 October]. Available
683 from: <http://www.eucast.org>
- 684 47. Brown LB, Krysiak R, Kamanga G, Mapanje C, Kanyamula H, Banda B, et al.
685 *Neisseria gonorrhoeae* antimicrobial susceptibility in Lilongwe, Malawi, 2007. *Sex Transm*
686 *Dis.* 2010;37(3):169-72. Epub 2009/11/11. doi: 10.1097/OLQ.0b013e3181bf575c. PubMed
687 PMID: 19901860.
- 688 48. Ayinde O, Ross JDC. Time to resolution of genital symptoms for uncomplicated
689 gonorrhoea: a prospective cohort study. *Sex Transm Infect.* 2020;sextrans-2020-054626. doi:
690 10.1136/sextrans-2020-054626.
- 691 49. Sultan B, Benn P, Schembri G, Patel H, Brima N, Alexander S, et al. Test of cure
692 study: a feasibility study to estimate the time to test of cure (TOC) for *Neisseria gonorrhoeae*
693 and *Chlamydia trachomatis* infections. *Sex Transm Infect.* 2020. Epub 2020/05/25. doi:
694 10.1136/sextrans-2019-054302. PubMed PMID: 32447324.
- 695 50. World Health Organization. Manual for the laboratory identification and antimicrobial
696 susceptibility testing of bacterial pathogens of public health importance in the developing
697 world : *Haemophilus influenzae*, *Neisseria meningitidis*, *Streptococcus pneumoniae*,
698 *Neisseria gonorrhoea*, *Salmonella* serotype Typhi, *Shigella*, and *Vibrio cholerae* / Principal
699 authors: Mindy J. Perilla ... [et al.]. Geneva: World Health Organization; 2003.
- 700 51. Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, et al.
701 Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for
702 uncomplicated gonorrhoea – challenges and opportunities. *Clinical Microbiology and*
703 *Infection.* 2020. doi: <https://doi.org/10.1016/j.cmi.2020.08.006>.
- 704 52. Gubish ER, Jr., Mace ML, Jr., Steiner SM, Williams RP. Assessment of attachment of
705 *Neisseria gonorrhoeae* to HeLa cells by double radiolabeling. *Infect Immun.*
706 1979;25(3):1043-50. Epub 1979/09/01. PubMed PMID: 40874; PubMed Central PMCID:
707 PMC414553.

- 708 53. Scangarella-Oman NE, Hossain M, Perry CR, Tiffany C, Powell M, Swift B, et al.
709 Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of
710 uncomplicated urogenital gonorrhoea. *Sexually Transmitted Infections*. 2023;99(1):64-9. doi:
711 10.1136/sextrans-2022-055518.
- 712 54. Veale DR, Goldner M, Penn CW, Ward J, Smith H. The intracellular survival and
713 growth of gonococci in human phagocytes. *J Gen Microbiol*. 1979;113(2):383-93. Epub
714 1979/08/01. doi: 10.1099/00221287-113-2-383. PubMed PMID: 117078.
- 715 55. Barcia-Macay M, Seral C, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
716 Pharmacodynamic evaluation of the intracellular activities of antibiotics against
717 *Staphylococcus aureus* in a model of THP-1 macrophages. *Antimicrob Agents Chemother*.
718 2006;50(3):841-51. Epub 2006/02/24. doi: 10.1128/AAC.50.3.841-851.2006. PubMed
719 PMID: 16495241; PubMed Central PMCID: PMCPMC1426441.
- 720 56. Van Bambeke F, Barcia-Macay M, Lemaire S, Tulkens PM. Cellular
721 pharmacodynamics and pharmacokinetics of antibiotics: current views and perspectives.
722 *Current opinion in drug discovery & development*. 2006;9(2):218-30. Epub 2006/03/29.
723 PubMed PMID: 16566292.
- 724 57. Kong FY, Rupasinghe TW, Simpson JA, Vodstrcil LA, Fairley CK, McConville MJ,
725 et al. Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men. *PLoS One*.
726 2017;12(3):e0174372. Epub 2017/03/30. doi: 10.1371/journal.pone.0174372. PubMed
727 PMID: 28350806; PubMed Central PMCID: PMCPMC5370104.

728

729 **Author contributions**

730 P.J conceptualisation, study design, model development, validation, figures, and
731 writing. JGW, DGR, PK methodology, study design, review, editing, supervision. All authors
732 reviewed the manuscript.

733 **Data availability**

734 All relevant data are within the paper and its Supporting Information files and the code is
735 available on GitHub at <https://github.com/pavijayasundara/NG-Treatment-Model>.

736 **Competing Interests**

737 Author's declare no competing interests. This work was supported by funding from the
738 National Health and Medical Research Council (NHMRC) [grant numbers APP1078068 and
739 APP1071269]. PJ was supported by a UNSW Sydney PhD tuition fee scholarship.